Iwilfin (eflornithine) — Highmark

Initial criteria

• Member has a diagnosis of neuroblastoma that is classified as high risk
• Member achieved at least a partial response to an anti‑GD2 immunotherapy (e.g., dinutuximab, naxitamab)

Reauthorization criteria

• Prescriber attests that the member has not experienced disease relapse
• Total cumulative duration of therapy with Iwilfin does not exceed 24 months

Approval duration

12 months